Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Can-Fite BioPharma Ltd
CANF | US
2.93
USD0.06
2.09%
CANF | US
About Can-Fite BioPharma Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.93
Open
2.89
High
3.12
Low
2.71
Can-Fite BioPharma Ltd. a clinical-stage biopharmaceutical company develops small molecule therapeutic products for the treatment of cancer liver inflammatory diseases and erectile dysfunction. The company's lead drug candidate Piclidenoson which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602 which is in pre-clinical trial for the treatment of erectile dysfunction. In addition the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop manufacture and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer inflammatory autoimmune and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva Israel.
View LessCANF | US
Risk
74.2
Sharpe
0.31
Luna's Score
48/100
Recommendation
Hold
Luna says (CANF | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
89.7%1 month
74.2%3 months
86.1%6 months
89.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
4.21
Price to book
7.06
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
0.10
Ent. to rev.
15.75
PEG
-
Other Fundamentals
EBITDA
-7.79M
MarketCap
17.86M
MarketCap(USD)
17.86M
Div. yield
-
Op. margin
-1.30K
Erngs. growth
-
Rev. growth
-19.40
Ret. on equity
-157.62
Short ratio
2.51
Short perc.
5.94
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.18
Range1M
1.21
Range3M
2.82
Volumes: Market Activity
Rel. volume
1.12
Price X volume
503.88K
